INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Systematic review / meta-analysis / 2019

Combining Astragalus-based Chinese medicines with chemotherapy was linked to improved tumor response rate and fewer adverse effects in colorectal cancer patients.

A meta-analysis of 22 studies involving 1,409 patients evaluated Astragalus-based Chinese medicines combined with chemotherapy versus chemotherapy alone for colorectal cancer. The combination was associated with an increased tumor response rate (RR: 1.52; 95% CI: 1.24-1.87; p < 0.0001) and improved quality of life on the KPS scale (RR: 2.51; 95% CI: 1.85-3.42; p < 0.00001). It also reduced adverse reactions such as neutropenia, anemia, thrombocytopenia, nausea/vomiting, diarrhea, and neurotoxicity, while hepatic and renal dysfunction did not differ significantly between groups.

Study type
Meta-analysis
Who was studied
1,409 subjects with colorectal cancer across 22 studies
What was measured
Tumor response rate, quality of life (KPS), adverse reactions

THE PAPER

Meta-Analysis of Astragalus-Containing Traditional Chinese Medicine Combined With Chemotherapy for Colorectal Cancer: Efficacy and Safety to Tumor Response.

Lin S, An X, Guo Y, Gu J, Xie T, Wu Q, Sui X. Front Oncol, 2019.

PubMed 31456940 ↗DOI 10.1002/ptr.5586 ↗

Cancer

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.